Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Celli BR, MacNee W (2004) Standards for the diagnosis and treatment of COPD. Eur Respir J 23:932–946
Global Obstructive Lung Disease Initiative. www.GOLD.org (updated 2006)
American Thoracic Society (1995) Standards for the diagnosis and case of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152:78–121
Pauwels RA et al (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163(5):1256–1276
Celli BR, Cote CG, Marin JM, Casanova C, de Montes Oca M, Mendez RA, Pinto Plata V, Cabral HJ (2004) The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350:1005–1012
Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE (2005) Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142:233–239
McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA (May 2007) TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 62(5):411–415
Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC (2002) Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR 51:1–16
Celli BR, Halbert RJ, Isonaka S, Schau B (2003) Population impact of different definitions of airways obstruction. Eur Respir J 22:268–273
Menezes A, Perez-Padilla R, Jardim J, Muiño A, Lopez M, Valdivia G, Montes de Oca M, Talamo C, Hallal P, Victoria C (2005) Prevalence of chronic obstructive pulmonary disease in five Latin American cities: the PLATINO study. Lancet 366:1875–1881
Pena VS, Miravitlles M, Gabriel R, Jimenez-Ruiz CA, Villasante C, Masa JF, Viejo JL, Fernandez-Fau L (2000) Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 118:981–989
Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N (2004) COPD group of the Hellenic Thoracic Society Prevalence of COPD in Greece. Chest 125:892–900
de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P (2004) European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 59:120–125
Talamo C, de Oca MM, Halbert R, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, Pertuze J, Moreno D, Menezes AM; PLATINO team (2007) Diagnostic labeling of COPD in five Latin American cities. Chest 131:60–67
Damarla M, Celli B, Mullerova H, Pinto-Plata V (2006) Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 51:1120–1124
Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J (2002) Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J 20:799–805
Anthonisen NR, Connett JE, Kiley JP, Altose M, Bailey W, Sonia Buist A, Conway W, Enright P, Kanner R, O’Hara P, Owens G, Scanlon P, Tashkin D, Wise R (1994) Effect of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the lung health study. JAMA 272:1497–1505
Casaburi R, Mahler D, Jones P, Wanner A, SanPedro G, ZuWallack R, Menjoge S, Serby C, Witek T (2002) A long term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19:217–224
Mahler D, Donohue J, Barbee R, Goldman M, Gross N, Wisnewiski M, Yancey S, Zakes B, Rickard K, Anderson W (1999) Efficacy of salmeterol xinoafate in the treatment of COPD. Chest 115:957–965
Jones P, Bosh T (1997) Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 155:1283–1289
Vincken W, van Noord J, Greefhorst A, Bantje Th, Kesten S, Korducki L, Cornelissen P (2002) On behalf of the Dutch/Belgian tiotropium study group. Improved health outcome in patients with COPD during 1 year treatment with tiorpium. Eur Respir J 19:209–216
ZuWallack R, Mahler D, Reilly D et al (2001) Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 119:1628–1630
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320:1297–1303
The Lung Health Study Research Group (2000) Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343:1902–1909
Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, Woodcock AA, Calverley PM (1992) Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 5:659–664
Friedman M, Serby C, Menjoge S, Wilson J, Hilleman D, Witek T (1999) Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 115:635–641
Belman MJ, Botnick WC, Shin JW (1996) Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153:967–975
O’Donnell D, Lam M, Webb K (1999) Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:542–549
O’Donnell D, Voduc N, Fitzpatrick M, Webb K (2004) Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 24:86–94
O’Donnell D, Flugre T, Gerken F, Hamilton A, Webb K, Aguilaniu B et al (2004) Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 23:832–840
Marin J, Carrizo S, Gascon M, Sanchez A, Gallego B, Celli B (2001) Inspiratory capacity, dynamic hyperinflation, breathlessness and exercise performance during the 6 minute walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163:1395–1400
Martinez F, Montes de Oca M, Whyte R, Stetz J, Gay S, Celli B (1997) Lung-volume reduction surgery improves dyspnea, dynamic hyperinflation and respiratory muscle function. Am J Respir Crit Care Med 155:2018–2023
Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR (2005) Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:591–597, 15 Mar 2005
Agustí AG, Noguera A, Sauleda J et al (2003) Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21:347–360
Nishimura K, Izumi T, Tsukino M, Oga T (2002) Dyspnea is a better predictor of 5-Year survival than airway obstruction in patients with COPD. Chest 121:1434–1440
Schols AM, Slangen J, Volovics L, Wouters EF (1998) Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1791–1797
Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP (1999) Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1856–1861
Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ, ZuWallack RL (1996) Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 9:431–435
Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR (2004) The 6-minute walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 1:28–33
Cote CG, Dordelly LJ, Celli BR (2007) Impact of chronic obstructive pulmonary disease exacerbations on patient centered outcomes. Chest 131(3):696–704
Imsfeld S, Bloch KE, Weder W, Russi EW (2006) The BODE index after lung volume reduction surgery correlates with survival. Chest 129:835–836
Nocturnal Oxygen Therapy Trial Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 93:391–398
Report of the Medical Research Council Working Party (1981) Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1:681–685
Brochard L, Mancebo J, Wysocki M et al (1995) Noninvasive ventilation for acute exacerbation of chronic obstructive pulmonary disease. N Engl J Med 333:817–822
Kramer N, Meyer T, Meharg J, Cece R, Hill NS (1995) Randomized prospective trial of non-invasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 151:1799–1806
Bott J, Caroll P, Conway J et al (1993) Randomized controlled trial of nasal ventilation in acute ventilatory failure due to obstructive lung disease. Lancet 341:1555–1559
National Emphysema Treatment Trial Research Group (2003) A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348:2059–2073
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J (2007) TORCH investigators. Salmetrol abd fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med 356:775–789, 22 Feb
Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O’Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T (2006) ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 173:1390–1413
Ries AL, Kaplan RM, Limberg TM, Prewitt LM (1995) The effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 122:823–832
Kottke TE, Battista RN, DeFriese GH (1988) Attributes of successful smoking cessation interventions in medical practice: a meta-analysis of 39 controlled trials. JAMA 259:2882–2889
Fiore M, Bailey W, Cohen S, Dorfman S, Goldstein M, Gritz E, Heyman R, Jaen C, Kottke T, Lando H, Mecklenburg R, Mullen P, Nett L, Robinson L, Sistzer M, Tommasello A, Villejo L, Wewers M (June 2000) Treating Tobacco use and dependence. U.S. Department Of Health and Human Services, Rockville
Jorenby DE, Leischow SG, Nides MA et al (1999) A controlled trial of sustained release buproprion, a nicotine patch or both for smoking cessation. N Engl J Med 340:685–691
Keating GM, Siddiqui MA (2006) Varnicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs 20:945–980
Celli B, ZuWallack R, Wang S, Kesten S (Nov 2003) Improvement of inspiratory capacity and hyperinflation with tiotropium in COPD patients with severe hyperinflation. Chest 124(5):1743–1748
O’Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K (2006) Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 130:647–656
Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della CG (2001) Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:778–784
Tantucci C, Duguet A, Similowski T, Zelter M, Derenne J-P, Milic-Emili J (1998) Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 12:799–804
Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K (2001) Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med Apr 163(5):1087–1092, 163:1087–1092
Ramirez-Venegas A, Ward J, Lentine T, Mahler D (1997) Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 112:336–340
Niwehowener D, Rice K, Cote C, Paulson D, Cooper JA, Korducki L et al (2005) Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once daily anticholinergic: a randomized trial. Ann Intern Med 143:317–326
Van Noord J, Aumann J, Jasnseens E, Smeets J, Verhaert J, Disse B et al (2005) omparison of tiotropium q.d, formoterol bid and both combined qd in patients with COPD. Respir J 26:214–222
Decramer M, Celli B, Tashkin D, Pawels R, Burkhart D, Cassino C, Kesten S (2004) Clinical trial design considerations in assessing long-term functional impacts of Tiotropium. J COPD 1:303–312
COMBIVENT Inhalation Aerosol Study Group (1994) In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 105:1411–1419
Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W (1994) A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD. Chest 105:1089–1094
Barnes PJ, Ito K, Adcock IM (2004) Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363:731–733
Rabe K, Bateman E, O’Donnell D, Witte S, Bredenbroker D, Bethke T (2005) Roflumilast- an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 366:563–571
Rennard S, Schachter N, Strek M, Rickard K, Amit O (2006) Cilomilast for COPD: results of a 6-month, placebo controlled study of a potent, selective inhibitor of posphodiesterase 4. Chest 129:56–66
Mahler D, Huang S, Tabrizzi M, Bell G (2004) Efficacy and safety of a monoclonal antibody recognizing interleukin – 8 in COPD: a pilot study. Chest 126:926–934
Rennard S, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J et al (2007) The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:926–934
Vestbo J, TORCH Study Group (2004) The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 24:206–210
Pauwels R, Lofdahl C, Laitinen L, Schouten J, Postma D, Pride N, Ohlson S (1999) Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 340:1948–1953
Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K (1999) Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised trial. Lancet 353:1819–1823
Sin DD (2001) Tu JV Inhaled corticosteroids and the risk for mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:580–584
Soriano JB, Vestbo J, Pride N, Kin V, Maden C, Maier WC (2002) Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20:819–824
Calverley PM, Boonsawat W, Cseke Z et al (2003) Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22:912–919
Szafranski W, Cukier A, Ramirez A et al (2003) Efficacy and safety of budesonide/formoterol in the management of COPD. Eur Respir J 21:74–81
Cazzola M, Dahl R (2004) Inhaled combination therapy with inhaled long-acting beta-2-agonist and corticosteroids in stable COPD. Chest 126:220–237
Aaron S, Vandemheen KL, Fergusson D, Maltais F, Borbeau J, Goldstein R et al (2007) Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146(8):545–555
Petty TL (1990) The National Mucolytic Study: results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 97:75–83
Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A (2005) Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365(9470):1552–1560, 30 Apr–6 May
Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Int Med 106:196–204
Saint S, Bent S, Vittinghoff F, Grady D (1995) Antibiotics in chronic obstructive pulmonary disease exacerbation. A metanalysis. JAMA 273:957–960
Stockley R, O’Bryan C, Pie A, Hill S (2000) Relationship of sputum color to nature and outpatient management of acute exacerbation of COPD. Chest 117:1638–1645
Miravitlles M (2002) Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med 9(4):191–197
Adams SG, Melo J, Luther M, Anzueto A (2000) Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 117:1345–1352
Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J (1999) A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160:1468–1472
Sandhaus R (2004) Alpha-1-antitrypsin deficiency: new and emerging therapies for alpha-1antytripsin deficiency. Thorax 59:904–909
Nichol KL, Baken L, Nelson A (1999) Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 130:397–403
Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J (1999) Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282:137–144
Snider G (1996) Reduction pneumoplasty for giant bullous emphysema Implications for surgical treatment of nonbullous emphysema. Chest 109:540–548
Patterson G, Maurer J, Williams T, Cardoso P, Scavuzzo M, Todd T (1999) Comparison of outcomes of double and single lung transplantation for obstructive lung disease. J Thorac Cardiovasc Surg 110:623–632
Bando K, Paradis I, Keenan R et al (1995) Comparison of outcomes after single and bilateral lung transplantation for obstructive lung disease. J Heart Lung Transplant 14:692–698
Orens J, Becker F, Lynch J III, Christensen P, Deeb G, Martinez F (1995) Cardiopulmonary exercise testing following allogeneic lung transplantation for different underlying disease states. Chest 107:144–149
Hosenpud J, Bennett L, Keck B, Boucek M, Novick R (2001) The registry of the International Society for Heart and Lung Transplantation: eighteenth official report-2001. J Heart Lung Transplant 20:805–815
Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, Egan T, Keshavjee S, Knoop C, Kotloff R, Martinez FJ, Nathan S, Palmer S, Patterson A, Singer L, Snell G, Studer S, Vachiery JL, Glanville AR (2006) Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25:745–575
Cooper J, Patterson G, Sundaresan R, Trulock E, Yusen R, Pohl M, Lefrak S (1996) Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg 112:1319–1330
Leyenson V, Furukawa S, Kuzma AM, Cordova F, Travaline J, Criner GJ (2000) Correlation of changes in quality of life after lung volume reduction surgery with changes in lung function, exercise, and gas exchange. Chest 118(3):728–735
Geddes D, Davies M, Koyama H, Hansell D, Pastorino U, Pepper J, Agent P, Cullinan P, MacNeill S, Goldstraw P (2000) Effect of lung-volume-reduction surgery in patients with severe emphysema. N Eng J Med 343:239–245
Criner G, Cordova G, Furukawa S, Kuzma A, Travaline J, Leyenson V, O’Brien G (1999) Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:2018–2027
Flaherty KR, Kazerooni EA, Curtis JL et al (2000) Short-term and long-term outcomes after bilateral lung volume reduction surgery: prediction by quantitative CT. Chest 119:1337–1346
Celli BR, Montes de Oca M, Mendez R et al (1997) Lung reduction surgery in severe COPD decreases central drive and ventilatory response to CO2. Chest 112:902–906
Flaherty KR, Kazerooni EA, Curtis JL, Iannettoni M, Lange L, Schork MA, Martinez FJ (2001) Short-term and long-term outcomes after bilateral lung volume reduction surgery: prediction by quantitative CT. Chest 119(5):1337–1346
National Emphysema Treatment Trial Research Group (NETT Research Group) (2001) Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 345:1075–1083
Szekely LA, Oelberg DA, Wright C et al (1997) Preoperative predictors of operative morbidity and mortality in COPD patients undergoing bilateral lung volume reduction surgery. Chest 111:550–558
Glaspole IN, Gabbay E, Smith JA, Rabinov M, Snell GI (2000) Predictors of perioperative morbidity and mortality in lung volume reduction surgery. Ann Thorac Surg 69:1711–1716
Hopkinson NS, Toma TP, Hansell DM, Goldstraw P, Moxham J, Geddes DM, Polkey MI (2005) Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 17:453–460
Ingenito EP, Loring SG, Moy ML et al (2001) Comparison of physiological and radiological screening for lung volume reduction surgery. Am J Respir Crit Care Med 163:1068–1073
Ingenito EP, Reilly JJ, Mentzer SJ, Swanson SJ, Vin R, Keuhn H, Berger RL, Hoffman A (2001) Bronchoscopic volume reduction: a safe and effective alternative to surgical therapy for emphysema. Am J Respir Crit Care Med 164(2):295–301
Reilley J, Chest Reilly J, Washko G, Pinto-Plata V, Velez E, Kenney L, Berger R, Celli B (2007) Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema. Chest 131:1108–1113
Agusti A, Sauleda J, Miralles C et al (2002) Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166:485–489
Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G (1997) Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 10:417–423
Reardon J, Awad E, Normandin E et al (1994) The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest 105:1046–1052
Goldstein RS, Gork EH, Stubbing D et al (1994) Randomized controlled trial of respiratory rehabilitation. Lancet 344:1394–1397
Wykstra PJ, Van Altens R, Kraan J et al (1994) Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J 7:269–273
Bendstrup KE, Ingenman Jensen J, Holm S, Bengtsson B (1997) Out-patient rehabilitation improves activities of daily living, quality of life, and exercise tolerance in chronic obstructive pulmonary disease. Eur Respir J 10:2801–2806
Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shields K, Turner-Lawlor PJ, Pyne N, Newcombe RG, Lonescu AA, Thomas J, Turnbridge J (2000) Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet 355:362–368
Guell R, Casan P, Belda J, Sangenis M, Morante F, Guyatt G, Sanchis J (2000) Long-term effects of outpatient rehabilitation of COPD: a randomized trial. Chest 117:976–983
Wedzicha JA, Bestall JC, Garrod R, Garnham R, Paul EA, Jones PW (1998) Randomised controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 12:363–369
Trooster T, Gosselink R (2000) Decramer M Short and long term effects of outpatients pulmonary rehabilitation in chronic obstructive pulmonary disease: a randomized trial. Am J Med 109:207–212
Maltais F, LeBlanc P, Simard C et al (1996) Skeletal muscle adaptation to endurance training in patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 154:436–444
Ries A, Kaplan R, Myers R, Prewett L (2003) Maintenance after ehabilitation in lung disease. A randomized trial. Am J Respir Crit Care Med 167:880–888
Cote CG, Celli BR (2005) Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 26:630–636
Prigatano GP, Parsons OA, Wright E, Levin DC, Hawryluk G (1983) Neuropsychologic test performance in mildly hypoxemic patients with chronic obstructive pulmonary disease. J Consult Clin Psychol 51:108–116
Grant I, Prigatano GP, Heaton RK, McSweeny AJ, Wright EC, Adams KM (1987) Progressive neuropsychologic impairment and hypoxemia. Relationship in chronic obstructive pulmonary disease. Arch Gen Psychiatry 44:999–1006
Criner GJ, Celli BR (1987) Ventilatory muscle recruitment in exercise with O2 in obstructed patients with mild hypoxemia. J Appl Physiol 63:195–200
Vyas MN, Banister EW, Morton JW, Grzybowski S (1971) Response to exercise in patients with chronic airway obstruction. II. Effects of breathing 40 percent oxygen. Am Rev Respir Dis 103:401–412
Dean NC, Brown JK, Himelman RB, Doherty JJ, Gold WM, Stulbarg MS (1992) Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia. Am Rev Respir Dis 146:941–945
Rodriguez-Roisin R (2000) Toward a consensus definition for COPD exacerbations. Chest 117:398s–401s
Celli B, Barnes P (2007) Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 29:1224–1238
Angus DL, RM CPM (1999) Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 345:456–460
Thompson WH, Nielson CP, Carvalho P et al (1996) Controlled trial of oral prednisone in outpatients with cute COPD exacerbation. Am J Respir Crit Care Med 154:407–412
Nieweohner DE, Erbland ML, Deupree RH et al (1999) Effect of glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 340:1941–1947
Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F (2001) Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomized placebo-controlled trial. Lancet 358:2020–2035
Seemungal TAR, Donaldson GC, Paul EA et al (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418–1422
Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57:847–852
Pinto-Plata V, Livnat G, Girish M, Cabral H, Masdin P, Linacre P, Drew R, Kenney L, Celli B (2007) Systemic cytokine, clinical and physiological changes in patients admitted with exacerbations of COPD. Chest 131:37–43
Casanova C, Celli BR, Tost L, Soriano E, Abreu J, Velasco V, Santolaria F (2000) Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest 118:1582–1590
Clinic E, Sturani C, Rossi A et al (2002) The Italian multicenter study on non-invasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 20:529–538
Barnes PJ, Shapiro S, Pawels R (2003) Chronic obstructive pulmonary disease; molecular and cellular mechanisms. Eur Respir J 22:672–688
Wouters E, Creutzberg E, Schols A (2002) Systemic effects of COPD. Chest 121:127S–130S
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Celli, B.R. (2011). Management Guidelines for Chronic Obstructive Pulmonary Disease. In: Hanania, N., Sharafkhaneh, A. (eds) COPD. Respiratory Medicine. Humana Press. https://doi.org/10.1007/978-1-59745-357-8_5
Download citation
DOI: https://doi.org/10.1007/978-1-59745-357-8_5
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-949-9
Online ISBN: 978-1-59745-357-8
eBook Packages: MedicineMedicine (R0)